Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)
Authors not listed
ADC Therapeutics S.A. · 2022
Abstract
The main objective of the trial is to assess the efficacy and tolerability of Lonca-R in unfit and frail participants with previously untreated DLBCL.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-06 MST
Cite this
APA
Anonymous. (2022). A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9). <em>ADC Therapeutics S.A.</em>. https://clinicaltrials.gov/study/NCT05144009
Vancouver
Anonymous. A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9). ADC Therapeutics S.A.. 2022.
BibTeX
@misc{anon2022APhase,
title = {A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)},
author = {Anonymous},
journal = {ADC Therapeutics S.A.},
year = {2022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Hoffmann-La Roche 2019
Open access · US-GOV
A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients With Diffuse Large B-Cell Lymphoma Following First-Line Immunotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
Sun Yat-sen University 2026
Open access · US-GOV
A Multicenter, Phase Ib/II Clinical Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide for Untreated Elderly Diffuse Large B-cell Lymphoma Patients With Double Expression of MYC and BCL2
University College, London 2023
Open access · US-GOV
Phase II Study of Acalabrutinib and Rituximab for Elderly or Frail Patients With Previously Untreated Mantle Cell Lymphoma
AstraZeneca 2024
Open access · US-GOV
A Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With Diffuse Large B-Cell Lymphoma (ACRUE)
Xiaohui He 2025
Open access · US-GOV
A Multicenter, Prospective Phase Ⅱ Clinical Study of R-mini-MCOP(Rituximab / Mitoxantrone Liposome / Cyclophosphamide / Vincristine / Prednisone) in the Treatment of Elderly, Previously Untreated Diffuse Large B-cell Lymphoma
The First Affiliated Hospital with Nanjing Medical University 2012
Open access · US-GOV